DE69635899D1 - Polypeptid, das die differenzierung unterdrueckt - Google Patents

Polypeptid, das die differenzierung unterdrueckt

Info

Publication number
DE69635899D1
DE69635899D1 DE69635899T DE69635899T DE69635899D1 DE 69635899 D1 DE69635899 D1 DE 69635899D1 DE 69635899 T DE69635899 T DE 69635899T DE 69635899 T DE69635899 T DE 69635899T DE 69635899 D1 DE69635899 D1 DE 69635899D1
Authority
DE
Germany
Prior art keywords
polypeptide
differentiation
suppressing differentiation
supression
efficacious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635899T
Other languages
English (en)
Other versions
DE69635899T2 (de
Inventor
Seiji Sakano
Akira Itoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Industry Co Ltd, Asahi Kasei Kogyo KK filed Critical Asahi Chemical Industry Co Ltd
Publication of DE69635899D1 publication Critical patent/DE69635899D1/de
Application granted granted Critical
Publication of DE69635899T2 publication Critical patent/DE69635899T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69635899T 1995-11-17 1996-11-15 Polypeptid, das die differenzierung unterdrueckt Expired - Lifetime DE69635899T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP29961195 1995-11-17
JP29961195 1995-11-17
JP31181195 1995-11-30
JP31181195 1995-11-30
PCT/JP1996/003356 WO1997019172A1 (fr) 1995-11-17 1996-11-15 Polypeptide suppresseur et de differenciation

Publications (2)

Publication Number Publication Date
DE69635899D1 true DE69635899D1 (de) 2006-05-04
DE69635899T2 DE69635899T2 (de) 2006-11-23

Family

ID=26561997

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635899T Expired - Lifetime DE69635899T2 (de) 1995-11-17 1996-11-15 Polypeptid, das die differenzierung unterdrueckt

Country Status (7)

Country Link
US (5) US6337387B1 (de)
EP (1) EP0861894B1 (de)
JP (1) JP4283891B2 (de)
AT (1) ATE319827T1 (de)
AU (1) AU716889B2 (de)
DE (1) DE69635899T2 (de)
WO (1) WO1997019172A1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
ES2334953T3 (es) 1995-06-28 2010-03-17 Imperial Cancer Research Technology Limited Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos.
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
JP4283891B2 (ja) 1995-11-17 2009-06-24 旭化成株式会社 分化抑制ポリペプチド
US6716974B1 (en) * 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US6291210B1 (en) 1996-07-16 2001-09-18 Asahi Kasei Kabushiki Kaisha Differentiation inhibitor
CN1160371C (zh) * 1996-11-07 2004-08-04 洛伦蒂斯有限公司 Notch蛋白及其配体
US6887475B1 (en) 1996-11-07 2005-05-03 Lorantis Limited Notch
EP0972041B2 (de) * 1997-04-04 2017-01-18 Millennium Pharmaceuticals, Inc. Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
JP4171528B2 (ja) 1997-05-14 2008-10-22 旭化成株式会社 新規な分化抑制剤
CA2295439A1 (en) * 1997-06-18 1998-12-23 Zymogenetics, Inc. Mammalian neuro-growth factor like protein
US6136952A (en) * 1997-06-25 2000-10-24 University Of Washington Human jagged polypeptide, encoding nucleic acids and methods of use
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6436650B1 (en) 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
EP1518930B1 (de) * 1998-10-13 2007-05-30 Genentech, Inc. Verfahren und Zusammenstzung zur Hemmung des Wachtums von neoplastischen Zellen
CA2347835A1 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU776393B2 (en) * 1998-12-23 2004-09-09 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
AU2600800A (en) * 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20040023324A1 (en) * 2000-08-25 2004-02-05 Seiji Sakano Stem cell culture medium and culture method by using the same
WO2002018544A2 (en) * 2000-08-31 2002-03-07 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CA2430989A1 (en) 2000-12-06 2002-06-13 Robert J. Hariri Method of collecting placental stem cells
WO2002063962A1 (en) * 2001-02-14 2002-08-22 Hariri Robert J Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
EP2316919B1 (de) 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
EP2292091A1 (de) 2002-02-13 2011-03-09 Anthrogenesis Corporation Embryoartige Stammzellen aus der Post Partum Plazenta von Säugetieren sowie Anwendungszwecke und Behandlungsverfahren, bei denen diese Zellen verwendet werden
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
MXPA04011851A (es) * 2002-05-30 2005-03-31 Celgene Corp Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos.
KR101042448B1 (ko) 2002-11-26 2011-06-16 안트로제네시스 코포레이션 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
MXPA05008445A (es) * 2003-02-13 2005-10-18 Anthrogenesis Corp Uso de sangre del cordon umbilical para tratar individuos que tienen una enfermedad, un trastorno o una afeccion.
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7795404B1 (en) 2003-08-08 2010-09-14 Five Prime Therapeutics, Inc. Human soluble notch receptor ligands
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
EP1694328A4 (de) * 2003-12-02 2010-02-17 Celgene Corp Verfahren und zusammensetzungen zur behandlung und versorgung von hämoglobinopathie und anämie
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US7794742B2 (en) * 2005-02-08 2010-09-14 University Of Washington Devices for promoting epithelial cell differentiation and keratinization
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2009513708A (ja) 2005-10-31 2009-04-02 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
JP5550235B2 (ja) 2005-12-29 2014-07-16 アントフロゲネシス コーポレーション 胎盤幹細胞集団
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
CA2654716A1 (en) * 2006-06-09 2007-12-21 Anthrogenesis Corporation Placental niche and use thereof to culture stem cells
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CN103356711A (zh) * 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
US20100172830A1 (en) * 2007-03-29 2010-07-08 Cellx Inc. Extraembryonic Tissue cells and method of use thereof
EP2155249A4 (de) * 2007-05-15 2011-11-16 Oncomed Pharm Inc Zusammensetzungen und verfahren zur diagnostizierung und behandlung von krebs
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
KR20160092062A (ko) * 2007-09-26 2016-08-03 안트로제네시스 코포레이션 인간 태반 관류액으로부터의 혈관형성 세포
AU2008307633C1 (en) 2007-09-28 2015-04-30 Celularity Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
KR20100100855A (ko) * 2007-11-07 2010-09-15 안트로제네시스 코포레이션 조산 합병증의 치료에 있어서의 제대혈의 용도
KR20180108887A (ko) * 2008-08-20 2018-10-04 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
JP6169316B2 (ja) * 2008-08-20 2017-07-26 アンスロジェネシス コーポレーション 改良型細胞組成物およびその作製方法
MX2011001992A (es) * 2008-08-22 2011-03-29 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
RU2562154C2 (ru) * 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
DK2375907T3 (da) * 2008-11-21 2019-06-11 Celularity Inc Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
PL3072526T3 (pl) 2009-10-16 2019-04-30 Oncomed Pharm Inc Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem DLL4 i środków antyhipertensyjnych
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
ES2646750T3 (es) * 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
KR20190076060A (ko) 2010-04-07 2019-07-01 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 혈관신생
EP2555783A1 (de) 2010-04-08 2013-02-13 Anthrogenesis Corporation Behandlung von sarkoidose mithilfe von stammzellen aus der plazenta
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012061146A1 (en) 2010-10-25 2012-05-10 The Children's Hospital Of Philadelphia Compositions and methods for the generation of platelets and methods of use thereof
US20120171161A1 (en) 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
WO2012092480A1 (en) 2010-12-30 2012-07-05 Anthirogenesis Corporation Compositions comprising amnion derived adherent cells and platelet-rich plasma
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
EP2861238A4 (de) 2012-06-05 2016-03-16 Capricor Inc Optimierte verfahren zur erzeugung von herzstammzellen aus herzgewebe und deren verwendung in der herztherapie
EP2882445B1 (de) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomen und mikroribonukleinsäuren zur geweberegeneration
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3200808A4 (de) 2014-10-03 2018-05-16 Cedars-Sinai Medical Center Kardiosphären-zellen und durch diese zellen sekretierte exosomen bei der behandlung von muskeldystrophie
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (de) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-spezifischer anti-vegf/dll4-antikörper zur verwendung bei der behandlung von platin-resistentem eierstockkrebs
EP3402543B1 (de) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Aus kardiosphäre stammende zellen und durch solche zellen sekretierte exosomen in der behandlung von herzversagen mit konservierter auswurffraktion
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (de) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center Kardiosphärenzellen und deren extrazelluläre vesikel zur verzögerung oder umkehr des alterungsprozesses und altersbedingten erkrankungen
WO2018195210A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
WO1993012141A1 (en) * 1991-12-11 1993-06-24 Yale University Nucleotide and protein sequences of the serrate gene and methods based thereon
US5869282A (en) * 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
US5864020A (en) 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
WO1996011212A1 (fr) 1994-10-07 1996-04-18 Asahi Kasei Kogyo Kabushiki Kaisha Nouveau ligand de tyrosine kinase de type recepteur
ES2334953T3 (es) * 1995-06-28 2010-03-17 Imperial Cancer Research Technology Limited Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos.
JP4283891B2 (ja) * 1995-11-17 2009-06-24 旭化成株式会社 分化抑制ポリペプチド

Also Published As

Publication number Publication date
US20050130271A1 (en) 2005-06-16
WO1997019172A1 (fr) 1997-05-29
JP4283891B2 (ja) 2009-06-24
ATE319827T1 (de) 2006-03-15
US7179622B2 (en) 2007-02-20
US7198918B2 (en) 2007-04-03
US20050164348A1 (en) 2005-07-28
US20050130268A1 (en) 2005-06-16
EP0861894A1 (de) 1998-09-02
US7141379B2 (en) 2006-11-28
US6337387B1 (en) 2002-01-08
DE69635899T2 (de) 2006-11-23
EP0861894A4 (de) 2002-08-07
EP0861894B1 (de) 2006-03-08
US20020128197A1 (en) 2002-09-12
US7253265B2 (en) 2007-08-07
AU7587696A (en) 1997-06-11
AU716889B2 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
DE69635899D1 (de) Polypeptid, das die differenzierung unterdrueckt
EP1439230A3 (de) Menschliche transmembranprotein TMP-2 gen
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
NO960309L (no) Agonister og antagonister for humaninterleukin-10
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
EE200200323A (et) RG1 polüpeptiidi kodeeriv DNA
EP0988316A4 (de) Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind.
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
ATE356205T1 (de) Milcherzeugungsassoziiertes immunotropisches rinderprotein (cd14), kodierendes gen und verwendung zur aktivierung von b-zellen
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
DE60129688D1 (de) Die menschliche beta-1a-untereinheit des potential-abhängigen natriumkanals und deren verwendungen
AU6860294A (en) New chondrocyte proteins
CA2236679A1 (en) Differentiation-suppressive polypeptide
EP0723016A3 (de) Leukocyten-aktivierender Faktor
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
AU5276296A (en) Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells
EP0787798A3 (de) GRP17 Gen
EP0960935A4 (de) Neuer cxc chemokinrezeptor aus maus
AR242636A1 (es) Gen con codificacion para actividad de factor estimulante de colonias de granulocitos humanos.
MX9800686A (es) Nueva proteina hmw humana mp52s.
NZ509284A (en) Tumour antigen peptide derived from SART-that binds to HLA-A24 antigen thereby facilitating recognition by a T call
MX9504057A (es) Proteina que tiene actividad tpo.
WO2001075050A3 (fr) Nouveau polypeptide, proteine humaine associee au transport vesiculaire 9, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition